[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,589,338
  • Shares Outstanding, K 139,722
  • Annual Sales, $ 67,670 K
  • Annual Income, $ -412,690 K
  • EBIT $ -421 M
  • EBITDA $ -405 M
  • 60-Month Beta 1.77
  • Price/Sales 24.49
  • Price/Cash Flow N/A
  • Price/Book 2.30

Options Overview Details

View History
  • Implied Volatility 89.62% (-10.18%)
  • Historical Volatility 90.97%
  • IV Percentile 45%
  • IV Rank 22.33%
  • IV High 154.61% on 10/27/25
  • IV Low 70.94% on 08/20/25
  • Expected Move (DTE 32) 1.96 (17.69%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 2,319
  • Volume Avg (30-Day) 3,159
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 67,992
  • Open Int (30-Day) 89,937
  • Expected Range 9.10 to 13.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.80
  • Number of Estimates 7
  • High Estimate $-0.68
  • Low Estimate $-0.94
  • Prior Year $-0.99
  • Growth Rate Est. (year over year) +19.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.94 +1.14%
on 07/20/26
18.48 -40.10%
on 07/02/26
-4.60 (-29.36%)
since 06/18/26
3-Month
10.94 +1.14%
on 07/20/26
18.48 -40.10%
on 07/02/26
-4.14 (-27.22%)
since 04/20/26
52-Week
7.95 +39.25%
on 11/21/25
28.25 -60.81%
on 10/20/25
-0.99 (-8.21%)
since 07/18/25

Most Recent Stories

More News
Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears

WOLF is now Wall Street's most shorted stock. Here's why bears keep piling on even after Wolfspeed's big debt overhaul.

SOUN : 6.34 (+1.12%)
RNECY : 12.1000 (+1.26%)
WOLF : 29.92 (+0.10%)
NTLA : 11.10 (-2.46%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.10 (-2.46%)
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published...

NTLA : 11.10 (-2.46%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.10 (-2.46%)
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.10 (-2.46%)
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE...

NTLA : 11.10 (-2.46%)
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying

Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.

ARKG : 38.39 (-3.71%)
REGN : 676.76 (+0.01%)
NTLA : 11.10 (-2.46%)
ARKK : 75.59 (+0.52%)
Intellia Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.10 (-2.46%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.10 (-2.46%)
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.10 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 12.17
2nd Resistance Point 12.01
1st Resistance Point 11.69
Last Price 11.10
1st Support Level 11.20
2nd Support Level 11.04
3rd Support Level 10.72

See More

52-Week High 28.25
Fibonacci 61.8% 20.50
Fibonacci 50% 18.10
Fibonacci 38.2% 15.70
Last Price 11.10
52-Week Low 7.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.